Silence, MiReven ink tumor collaboration
October 2012
SHARING OPTIONS:

LONDON—Silence Therapeutics PLC and MiReven Pty. Ltd. have signed an agreement to assess the delivery potential of Silence's proprietary delivery systems when combined with MiReven's microRNA-based therapeutics. Per the agreement, Silence will develop a miR-7 mimetic with its proprietary AtuPLEX, DACC and DBTC delivery systems to evaluate miR-7 in several cancer models. Silence will perform in- vitro and in-vivo studies of the formulated miR-7, and will receive an undisclosed fee.
 
"MiReven's founding scientists have developed a compelling body of preclinical data supporting the potential of miR-7 to suppress tumor growth, particularly in the many cancers known to be controlled by the EGF receptor signaling pathway, including glioblastoma. MiReven is currently testing drug-like versions of miR-7 in key models of human cancer," Stephen Thompson of MiReven said in a press release.

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.